American College of Rheumatology/ EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision
Authors' conclusion
Using the Boolean 2.0 criteria classifies more patients as achieving remission and increases the agreement with index-based remission criteria without jeopardizing predictive value for radiographic or functional outcomes.
Study context
- Population
- Participants with early or established rheumatoid arthritis (RA) in 4 RCTs comparing bDMARDs with MTX or placebo1,101 early RA, 947 established RA
- Participants
- 2,048 participants
- Comparison
- Boolean remission with patient global assessment (PtGA) threshold 2 cm (Boolean2.0) vs original threshold 1 cm (Boolean1.0); agreement with SDAI and CDAI remission
Methodological detailsexternal validation, pooled analysis of 4 RCTs
- External validation
- Pooled analysis of 4 RCTs
Primary result
As reported in the abstract
Proportion in remission · 6 months after treatment initiation
Proportion in remission · 6 months after treatment initiation
Established RA
Further findings
Agreement with SDAI or CDAI remission criteria
- Agreement better for Boolean2.0 than Boolean1.0, particularly in early disease
Prediction of radiographic nonprogression and HAQ score ≤0.5
- Boolean2.0, SDAI and CDAI had similar positive likelihood ratios (LRs)
- 3.8-4.3
- Omission of PtGA (BooleanX) worsened prediction of good functional outcomes
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
American College of Rheumatology/ EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision. Arthritis Rheumatol. Published 23 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →